In a study of veterans aged 65 years or older, new statin use lowered mortality and major adverse cardiovascular events (MACE) independent of frailty status, researchers
Compiling data from 7 clinical trials, researchers conclude that the small interfering RNA (siRNA) agent inclisiran was well tolerated during long-term treatment of dyslipidemias in
In a phase 1 study of 48 participants, lepodisiran reduced serum lipoprotein(a) concentrations through its actions on the production of apolipoprotein(a) in the liver. The
Statin use has plateaued at 35% of adults with little change since the release of the 2013 guidelines that expanded the number of Americans with
In high-risk patients with diabetes in a contemporary healthcare system, “significant gaps” remain in the use of guideline-directed statin intensity (GDSI) for primary prevention, a
A 1.5 million-participant study of incident cardiovascular disease shows that more than one-half of cases and about one-fifth of related deaths result from 5 modifiable
In a phase 1 pharmacokinetics and pharmacodynamics trial, muvalaplin was safe and well-tolerated and lowered lipoprotein(a) (Lp[a]) levels up to 65% after 14 days of daily
Compared with placebo in people with HIV infection, pitavastatin decreased the risk of major adverse cardiovascular events over a median follow-up of 5.1 years, researchers
Atorvastatin reduced the incidence of cardiac dysfunction among patients with lymphoma treated with anthracycline-based chemotherapy in the STOP-CA (Statins to Prevent the Cardiotoxicity of Anthracyclines)
A nationwide study from Denmark shows a greater LDL cholesterol response for adults aged 75 years or older to low- to moderate-intensity statins than in